Evaluation of Human Umbilical Cord Stem Cell Exosome Injections for Treating Hair Loss in Men with Androgenetic Alopecia

What this Trial Is About

This research aims to evaluate whether local scalp injections of human umbilical cord mesenchymal stem cell-derived exosomes hUCMSC-Exos can improve hair regrowth in men with androgenetic alopecia AGA, a chronic condition causing hair thinning due to hair follicle miniaturization. The study compares hUCMSC-Exos injections to placebo injections to understand if this new approach can better support hair follicle regeneration, measured by changes in hair density, thickness, and patient feedback. Participants are randomly assigned to receive either hUCMSC-Exos or placebo injections into the scalp. These injections are given intradermally at specified points, with a volume of 0.05 mL per point spaced 1 cm apart, repeated once every 4 weeks for a total of 3 sessions. The study is double-blinded, ensuring neither participants nor researchers know who receives the active treatment or placebo during the trial. Throughout the study, participants attend scheduled follow-up visits where their hair condition is assessed using photography and trichoscopy. They also complete questionnaires to evaluate quality of life and psychosocial impact. Researchers monitor safety and effectiveness by measuring changes in hair density, hair thickness, photographic scores, and patient satisfaction over a 24-week period. The trial is led by Zhang Han and aims to provide evidence on the potential of exosome therapy for hair loss.

Exosome Therapy for Male Androgenetic Alopecia